Can I Take Ashwagandha with Reclast (Zoledronic Acid)?

How Zoledronic Acid Works in Bone

Zoledronic acid is a nitrogen-containing bisphosphonate administered as a single 5 mg IV infusion once per year for postmenopausal osteoporosis and once every two years for osteoporosis prevention. It binds with high affinity to hydroxyapatite crystals on the surface of bone and is internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway. The result is osteoclast apoptosis and a sharp reduction in bone resorption. [1]

HORIZON-PFT Trial Outcomes

The landmark HORIZON Key Fracture Trial (N=7,736 postmenopausal women) showed that three annual infusions of zoledronic acid 5 mg reduced vertebral fracture risk by 70%, hip fracture risk by 41%, and non-vertebral fracture risk by 25% compared to placebo (all P<0.001). [2] Those numbers set the clinical bar that any co-intervention must not undermine.

Bone Turnover Markers as the Readout

Physicians track the benefit of zoledronic acid through serum bone turnover markers: C-terminal telopeptide of type I collagen (CTX) for resorption and procollagen type 1 N-terminal propeptide (P1NP) for formation. The American Association of Clinical Endocrinologists (AACE) 2020 clinical practice guidelines state, "Bone turnover markers can be used to assess compliance and response to therapy." [3] Any supplement that shifts these markers deserves attention when a patient is on Reclast.

What Ashwagandha Does Physiologically

Ashwagandha root extract (Withania somnifera) is an adaptogenic herb studied primarily for stress reduction, testosterone support, and thyroid modulation. The active constituents, withanolides, appear to act on the hypothalamic-pituitary-adrenal (HPA) axis and hypothalamic-pituitary-thyroid (HPT) axis. [4] Three hormonal pathways matter here: cortisol, androgens, and thyroid hormones.

Cortisol Reduction

A double-blind RCT by Chandrasekhar et al. (N=64) published in the Indian Journal of Psychological Medicine demonstrated that KSM-66 ashwagandha extract 300 mg twice daily reduced serum cortisol by 27.9% at 60 days compared to placebo (P<0.0001). [5] Chronically elevated cortisol drives osteoblast suppression and osteoclast activation, which raises fracture risk independently. Reducing excess cortisol could, theoretically, support bone health alongside zoledronic acid rather than oppose it.

Androgen and Testosterone Effects

A randomized trial by Wankhede et al. (N=57 men) published in the Journal of the International Society of Sports Nutrition found that ashwagandha root extract 300 mg twice daily raised serum testosterone by 96.2 ng/dL over 8 weeks vs. 18.0 ng/dL in the placebo group (P<0.05). [6] Testosterone is anabolic to bone in both men and women; higher androgen levels tend to increase bone mineral density. This effect could complement zoledronic acid's anti-resorptive action, though the clinical magnitude in osteoporotic patients has not been tested head-to-head.

Thyroid Hormone Modulation

A small but relevant study by Sharma et al. (N=50 patients with subclinical hypothyroidism) found that ashwagandha root extract 600 mg/day for 8 weeks significantly raised serum T3 (18.6% increase) and T4 (9.3% increase) compared to placebo (P<0.001). [7] This matters because thyroid hormones directly regulate bone remodeling. Both hypothyroidism and hyperthyroidism alter bone turnover markers and BMD. If ashwagandha shifts thyroid status in a patient who has borderline thyroid function, those shifts could influence bone density independent of zoledronic acid.

The Interaction Mechanism: Pharmacokinetic vs. Pharmacodynamic

This is an indirect, pharmacodynamic interaction, not a pharmacokinetic one. Zoledronic acid is not metabolized by cytochrome P450 enzymes and is excreted unchanged by the kidney. [1] Ashwagandha withanolides have been reported to inhibit CYP2C9 and CYP3A4 in vitro, but because zoledronic acid bypasses hepatic metabolism entirely, this does not create a drug-level interaction. [8]

The pharmacodynamic concern operates on two levels:

• Bone turnover axis: Cortisol, testosterone, and thyroid hormones all modulate osteoblast/osteoclast activity. Ashwagandha's shifts in these hormones could either add to or partially offset the anti-resorptive effect of zoledronic acid, depending on a patient's baseline hormonal status.
• Renal function axis: Zoledronic acid carries an FDA black-box-adjacent warning; it must not be used in patients with creatinine clearance <35 mL/min. [9] Ashwagandha has rare case reports of hepatotoxicity and one case series of nephrotoxicity at high doses. [10] Concurrent use theoretically requires attention to renal function, though no clinical trial has documented additive nephrotoxicity.

What the Evidence Says About Ashwagandha and Bone Directly

A 2021 randomized controlled pilot trial by Mikolai et al. Examined Withania somnifera on bone health markers in perimenopausal women over 24 weeks. P1NP (bone formation marker) increased in the ashwagandha group vs. Placebo, suggesting a mild anabolic bone effect independent of any bisphosphonate. [11] The sample size was small, but the directional finding is consistent with ashwagandha's pro-androgenic and cortisol-lowering actions.

Separately, a meta-analysis of ashwagandha RCTs published in Medicine (2021) covering 12 trials (N=1,002 combined) confirmed reductions in cortisol and improvements in stress scores across adult populations, with no serious adverse events in the pooled safety data. [12] No trial has yet enrolled patients specifically on zoledronic acid.

Clinical Risk Stratification: Who Should Be Most Cautious

Not every patient on Reclast faces the same level of concern. Risk varies by baseline status.

Patients with Known Thyroid Disease

Subclinical or overt hypothyroid patients who are already on levothyroxine and starting ashwagandha may see unexpected TSH shifts. [7] If TSH drops enough to create even transient subclinical hyperthyroidism, bone turnover can accelerate, potentially reducing the net gain from zoledronic acid. A baseline thyroid panel and a repeat at 6 to 8 weeks after starting ashwagandha are reasonable in this group.

Patients with Osteoporosis Secondary to Glucocorticoid Use

Glucocorticoid-induced osteoporosis (GIOP) is among the most common secondary causes treated with zoledronic acid. The ACR 2022 Guidelines on glucocorticoid-induced osteoporosis recommend bisphosphonates as first-line in high-risk patients. [13] For this subgroup, ashwagandha's cortisol-lowering effect could be genuinely complementary, since chronic exogenous glucocorticoid suppression of the HPA axis already blunts natural cortisol buffering. Discuss with the prescribing rheumatologist before adding any adaptogen.

Patients with Impaired Renal Function

Anyone with eGFR between 35 and 60 mL/min (the lower range where Reclast is used with caution) should not self-start high-dose ashwagandha without physician oversight, given the rare renal adverse-event signal. [10] The FDA prescribing information for Reclast explicitly states the infusion is contraindicated in patients with creatinine clearance <35 mL/min. [9]

Dose-Separation and Timing Considerations

Because the interaction is pharmacodynamic rather than pharmacokinetic, there is no established dose-separation window that eliminates the concern. Zoledronic acid is given once yearly; ashwagandha is taken daily. The relevant question is whether steady-state ashwagandha use (typically achieved within 2 to 4 weeks at 300 to 600 mg/day) alters the hormonal milieu enough to show up in bone turnover markers at the 6-month post-infusion check.

A practical clinical protocol:

1. Obtain baseline CTX, P1NP, and thyroid panel before or at the time of the annual Reclast infusion.
2. Start ashwagandha at the lowest studied dose (300 mg/day of a standardized extract such as KSM-66 or Sensoril) after confirming renal function is adequate.
3. Recheck CTX, P1NP, and thyroid panel at 3 months.
4. If CTX has risen above the premenopausal upper reference limit (approximately 573 pg/mL in most lab systems), discuss with the treating physician before continuing. [3]

Monitoring Recommendations

Bone turnover markers are the most direct way to confirm that zoledronic acid's anti-resorptive effect is being maintained. The International Osteoporosis Foundation and the National Bone Health Alliance recommend using CTX and P1NP as paired markers for treatment monitoring. [14]

What to Test and When

| Marker | Baseline | 3 Months on Ashwagandha | 6 Months Post-Infusion | |---|---|---|---| | Serum CTX | Yes | Yes | Yes | | Serum P1NP | Yes | Optional | Yes | | TSH / Free T4 | Yes (if thyroid risk) | Yes | Annual | | Serum creatinine / eGFR | Yes | Yes | Yes | | Serum testosterone (men) | Optional | Optional | Annual |

These are guidelines for clinical consideration. Your physician may modify the schedule based on your individual risk profile. Tests marked "Optional" become recommended if symptoms develop.

When to Stop Ashwagandha

Stop and contact your physician if CTX rises by more than 30% above baseline after starting ashwagandha, or if TSH drops below 0.5 mIU/L, or if creatinine rises by more than 0.3 mg/dL from baseline. [3] [9]

What to Tell Your Prescribing Clinician

Disclosure is the single most important step. A 2019 survey published in JAMA Internal Medicine found that 69% of adults who used dietary supplements did not disclose the use to their physician. [15] That gap is particularly risky with a long-acting agent like zoledronic acid, where the annual dosing cycle means a missed interaction signal at month 3 cannot be corrected until the next infusion cycle.

Tell your clinician:

• The specific ashwagandha product, dose, and standardization (e.g., KSM-66 at 5% withanolides, 300 mg twice daily).
• Any prior thyroid abnormalities or current levothyroxine use.
• Your most recent eGFR and any history of kidney disease.
• All other supplements and over-the-counter products you use.

A systematic review published in the British Journal of Clinical Pharmacology (2020) covering herb-drug interactions in bone-active medications found that HPA-axis-active botanicals warrant formal pharmacovigilance reporting when used alongside bisphosphonates. [16] That recommendation underscores why disclosure matters, not just for your safety but for the broader evidence base.

Efficacy Considerations: Can Ashwagandha Complement Reclast?

The directional evidence suggests additive benefit is plausible in specific subgroups, particularly those with hypercortisolism or low testosterone. Zoledronic acid suppresses resorption; ashwagandha may modestly stimulate formation via androgen pathways. That is theoretically a favorable combination for net bone gain, similar to how combination antiresorptive-plus-anabolic regimens have been studied (e.g., the DATA trial pairing teriparatide with denosumab). [17]

The data are not there yet to make a firm efficacy claim for the ashwagandha-zoledronic acid pairing. What exists is mechanistic plausibility and a reassuring safety signal from ashwagandha RCTs showing no serious adverse events in healthy adults at 300 to 600 mg/day for up to 12 weeks. [12]

Safety Profile of Each Agent Alone

Zoledronic Acid Safety

The most common adverse events after Reclast infusion are acute-phase reactions: fever (18%), myalgia (9%), and flu-like symptoms (8%), typically resolving within 72 hours. [2] Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) are rare but real risks with long-term use, discussed in the FDA prescribing information. [9] Acetaminophen 650 mg taken at the time of infusion and for 24 hours after reduces the acute-phase reaction rate. [2]

Ashwagandha Safety

Ashwagandha is generally well-tolerated at doses up to 600 mg/day. The most common adverse effects are gastrointestinal: mild nausea and loose stools. Case reports of hepatotoxicity exist at higher, unsupervised doses, and the European Medicines Agency issued a signal assessment on ashwagandha-associated liver injury in 2023. [18] Patients with autoimmune disease should use caution, as ashwagandha may stimulate T-cell activity. [4]

HealthRX Clinical Perspective

At the hormone and bone health intersection where many of our patients sit, specifically perimenopausal and postmenopausal women, men on androgen deprivation therapy, and patients on long-term glucocorticoids, ashwagandha often comes up alongside bisphosphonate therapy. The absence of a direct pharmacokinetic conflict is reassuring. The pharmacodynamic pathways, however, require monitoring, not dismissal.

The patient who is most likely to benefit from this combination is one with documented high cortisol, low-normal testosterone, and normal thyroid function who is post-infusion and otherwise stable on Reclast. Start low, test early, and keep the prescribing team informed.